Your browser is no longer supported. Please, upgrade your browser.
KMDA Kamada Ltd. daily Stock Chart
Kamada Ltd.
Index- P/E15.41 EPS (ttm)0.55 Insider Own19.82% Shs Outstand44.52M Perf Week-3.20%
Market Cap376.67M Forward P/E- EPS next Y-0.04 Insider Trans0.00% Shs Float27.36M Perf Month8.12%
Income- PEG2.57 EPS next Q0.11 Inst Own38.76% Short Float0.33% Perf Quarter47.90%
Sales133.68M P/S2.82 EPS this Y-41.80% Inst Trans- Short Ratio0.66 Perf Half Y22.61%
Book/sh3.81 P/B2.22 EPS next Y-112.50% ROA- Target Price9.00 Perf Year48.16%
Cash/sh- P/C- EPS next 5Y6.00% ROE- 52W Range4.40 - 9.91 Perf YTD23.87%
Dividend- P/FCF- EPS past 5Y117.91% ROI- 52W High-14.63% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low92.27% ATR0.59
Employees429 Current Ratio- Sales Q/Q24.20% Oper. Margin- RSI (14)52.33 Volatility8.08% 5.81%
OptionableNo Debt/Eq- EPS Q/Q6.00% Profit Margin- Rel Volume0.96 Prev Close8.83
ShortableYes LT Debt/Eq- EarningsMay 18 BMO Payout- Avg Volume136.28K Price8.46
Recom- SMA201.70% SMA507.83% SMA20029.89% Volume131,467 Change-4.19%
Feb-02-18Initiated Chardan Capital Markets Buy $7
Jun-25-20 08:46AM  
Jun-24-20 10:45AM  
Jun-17-20 08:26AM  
Jun-12-20 10:29PM  
May-18-20 11:30AM  
May-11-20 07:00AM  
May-05-20 12:30PM  
Apr-27-20 07:00AM  
Mar-13-20 12:40PM  
Mar-12-20 10:36AM  
Mar-11-20 08:03AM  
Feb-26-20 09:30AM  
Feb-12-20 07:00AM  
Feb-05-20 07:00AM  
Jan-21-20 07:00AM  
Jan-17-20 12:10PM  
Jan-07-20 07:00AM  
Dec-16-19 07:00AM  
Dec-09-19 07:00AM  
Dec-02-19 07:00AM  
Nov-30-19 10:04AM  
Nov-13-19 08:15AM  
Nov-07-19 07:00AM  
Nov-04-19 10:30AM  
Oct-29-19 08:00AM  
Sep-24-19 07:00AM  
Sep-03-19 07:00AM  
Aug-08-19 07:00AM  
Aug-07-19 03:23PM  
Aug-06-19 08:35AM  
Jul-31-19 07:00AM  
Jul-30-19 10:38AM  
Jul-19-19 10:57AM  
Jul-18-19 08:25AM  
Jul-17-19 07:40AM  
Jul-16-19 09:53AM  
Jun-28-19 04:04PM  
May-17-19 02:30PM  
May-14-19 08:25AM  
May-13-19 06:47PM  
May-07-19 05:45PM  
May-01-19 05:45PM  
Apr-25-19 05:50PM  
Apr-24-19 09:30AM  
Apr-17-19 10:46AM  
Apr-16-19 07:00AM  
Apr-12-19 09:46AM  
Apr-11-19 10:43AM  
Apr-10-19 05:50PM  
Apr-09-19 11:24AM  
Apr-08-19 09:30AM  
Apr-05-19 09:29AM  
Apr-04-19 05:50PM  
Apr-02-19 10:45AM  
Apr-01-19 10:49AM  
Mar-29-19 10:36AM  
Mar-28-19 11:18AM  
Mar-27-19 10:48AM  
Mar-26-19 09:39AM  
Mar-25-19 11:05AM  
Mar-22-19 09:30AM  
Mar-19-19 11:57AM  
Mar-18-19 07:25AM  
Mar-14-19 07:00AM  
Mar-13-19 09:13AM  
Mar-12-19 09:12AM  
Mar-08-19 10:04AM  
Mar-07-19 09:06AM  
Feb-27-19 09:00AM  
Feb-25-19 08:05AM  
Feb-20-19 09:10AM  
Feb-12-19 06:22AM  
Feb-06-19 07:00AM  
Feb-05-19 07:00AM  
Jan-30-19 07:00AM  
Jan-02-19 07:00AM  
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.